Mycenax Capacity Update October 2024: ADC

Mycenax Biotech Inc. delivers a comprehensive solution for Antibody-Drug Conjugates (ADCs), offering a full suite of end-to-end services that includes feasibility studies, process development, and GMP production, in close collaboration with Krisan Biotech Inc. Our extensive expertise encompasses both site-specific and stochastic conjugation techniques, enabling us to ensure the production of high-quality ADCs tailored to meet the unique requirements of our clients.

Our dedicated ADC GMP facilities are designed to meet Occupational Exposure Band (OEB) 5 and 6 standards, ensuring the safety and integrity of our processes. We offer scalable capacities that range from 0.01 grams to 1000 grams for ADC drug substances, accommodating a wide array of project needs. Additionally, our capabilities extend to the production of ADC drug products, with the ability to fill up to 5000 vials per batch, ensuring efficiency and responsiveness in meeting market demands.

At Mycenax, we are committed to advancing the development and commercialization of innovative therapeutics, positioning ourselves as a trusted partner in the biopharmaceutical landscape.